Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

Corcept Therapeutics is a strong investment opportunity due to its positive international sales growth, recent CHMP recommendation for EU approval of Lifyorli, and planned relacorilant NDA resubmission for Cushing's syndrome. These factors, along with increased physician awareness and early adoption of Lifyorli in the US, suggest potential for significant market expansion globally and a favorable benefit-risk profile.

Bears say

Corcept Therapeutics is expected to see an increase in its stock price due to its strong financials, including positive revenue guidance of $1B at the midpoint, record starts for Korlym patients, and the successful completion of the pharmacy transition. Additionally, the company's pipeline has promising potential for treating serious disorders, providing an avenue for future growth. However, there are risks involved in the stock, such as potential commercial, clinical, and regulatory setbacks, as well as legal and intellectual property issues within the industry.

Corcept Therapeutics (CORT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 5 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.